Viewpoints

The bio/pharma outsourcing industry continues to be integral in the development and manufacture of medicines.

Guest contributor B.S. Sathya Durga discusses the importance of modernizing India's pharmaceutical manufacturing industry.

Guest contributor Frederic Kahn discusses the state of the Indian pharmaceutical manufacturing industry.

Researchers from the Telomere-to-Telomere Consortium have discovered new properties about junk DNA that could have wide-reaching implications.

The process of reshaping inevitably leads to fresh insights.

Change of roster does not change the goal line. We are all patients first.

The mission continues. Let science be the guide.

Vaccines define the path to putting pandemic restrictions and pain in the rear-view mirror.

Bio/pharmaceutical manufacturers have made a good first step toward global vaccination through pledging doses at no- to low-profit rates.

Innovation drives the development of emerging drug modalities.

As face masks start to come off, bio/pharma’s COVID-19 battle goes on.

Smart, accurate, science-based messaging is needed to advance bio/pharma science.

Bio/pharma works hard today to change the calendar to tomorrow.

Viewpoint: Mike Hennessy, Sr., founder and chairman of MJH Life Sciences, commends the leadership of the pharmaceutical industry in combatting the COVID-19 pandemic.

A complicated vaccination rollout and mixed messages may derail the pandemic endgame

The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.

Time sure flies, except when you are waiting for something to happen.

FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

Having a better understanding about compliance will be of benefit when looking for a job or for furthering one’s career, says Siegfried Schmitt, PhD, vice-president, technical, Parexel Consulting.

Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.

Characterizing and controlling protein aggregation is vital to ensure safety and efficacy of a biopharmaceutical product. In this interview, important aspects of protein aggregation and the tools available to address this issue are discussed.

Emergency actions to protect patients and the drug supply may have long-term implications.

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

Nearly four decades after the first diagnosis, the fight to treat HIV/AIDs continues.

FDA report says drug shortages are underappreciated and patients pay a price.

Climbing out of a reputation hole can start with adopting a quality culture.

FDA and USP take sides in debate on biologic drug standards.

A good working relationship between sponsor and contractor will become invaluable when an OOS occurs, says Susan J. Schniepp, executive vice-president of post-approval pharma and distinguished fellow, Regulatory Compliance Associates.

Do patients get what they pay for when they demand cheaper drugs?